Alignment Healthcare (ALHC) Expected to Announce Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect Alignment Healthcare to post earnings of ($0.14) per share and revenue of $889.83 million for the quarter.

Alignment Healthcare Stock Performance

ALHC opened at $18.30 on Thursday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60. The business’s 50-day simple moving average is $16.78 and its 200 day simple moving average is $13.99. The firm has a market capitalization of $3.51 billion, a PE ratio of -23.77 and a beta of 1.32. Alignment Healthcare has a 52-week low of $5.02 and a 52-week high of $21.06.

Insider Transactions at Alignment Healthcare

In other news, President Dawn Christine Maroney sold 30,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.72, for a total transaction of $411,600.00. Following the sale, the president now directly owns 1,576,097 shares of the company’s stock, valued at approximately $21,624,050.84. This represents a 1.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Hakan Kardes sold 14,500 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $14.98, for a total value of $217,210.00. Following the completion of the transaction, the insider now directly owns 295,444 shares of the company’s stock, valued at approximately $4,425,751.12. This trade represents a 4.68 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,171,355 shares of company stock valued at $34,961,517. 6.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on ALHC shares. Robert W. Baird upped their price target on shares of Alignment Healthcare from $17.00 to $22.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 15th. JPMorgan Chase & Co. boosted their price target on Alignment Healthcare from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, March 6th. Bank of America raised their price objective on Alignment Healthcare from $15.50 to $18.50 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Piper Sandler boosted their target price on Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Finally, Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Alignment Healthcare in a report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.61.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.